NEW YORK – Life science company Deepcell raised $73 million in a Series B funding round led by Koch Disruptive Technologies, the company announced on Thursday.
Deepcell intends to use its new funding to advance development and early commercial introduction of its single-cell analysis platform.
"The new funding will help us to accelerate our growth, develop our platform, and take a major step toward full commercialization," Deepcell CEO and Cofounder Maddison Masaeli said in a statement.
Deepcell's platform uses cell imaging, microfluidics, and artificial intelligence to analyze and sort cells based on visual features. The platform is designed to keep cells intact during isolation and analysis, enabling downstream cellular characterization of single cells, with applications including understanding cellular heterogeneity and improved cell subtyping.
Deepcell is exploring the applications of its platform in collaborations, including one with TGen, to characterize the melanoma microenvironment, and with Stanford University, to help build a broad-scale human cell atlas.
Other investors in this funding round included Bridger Healthcare, Horizons Ventures, and Casdin Capital. Returning investors from previous rounds include Andreessen Horowitz and Bow Capital as well as Jeff Dean, head of Google Brain, and Matt Mcllwain, managing director at Madrona Venture Group.
This Series B financing brings Deepcell's overall funding to nearly $100 million since the company's inception in 2017.